ClinicalTrials.gg
Not yet recruitingNCT07067450Updated Jul 16, 2025

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

An interventional study of Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab) and Observation in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Sichuan University · Not applicable, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma — 95 open to participants now, 109 under way, 17 of them phase 3. A drug class: Immune checkpoint inhibitors · Esophageal Squamous Cell Carcinoma.

Planned enrollment
57th of 197
98 · median 50
Started
2025
with 17 others
No phase
10 of 197
3 open now
Primary completion
2026-12
later than 52 of 108 live
Registered
168th of 197
by date

Among the 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma, this one is the 57th largest by planned enrollment, is one of 18 that started in 2025, is one of 10 with no phase, reaches primary completion later than 52 of the 108 other live ones, and was the 168th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

95 of the 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

90 more — sign in →

By country, each count listing its studies:

All 95 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing Immune checkpoint inhibitors in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

Patients with esophageal cancer still face a high risk of recurrence after receiving neoadjuvant chemoradiotherapy (nCRT) combined with radical surgery, especially for those who do not achieve pathological complete response (non-pCR). Compared with the overall non-pCR population, the subgroup with lymph node positivity has a significantly worse prognosis. The CheckMate 577 study confirmed that in patients with locally advanced resectable esophageal cancer or esophageal-gastric junction cancer, adjuvant treatment with nivolumab after nCRT significantly prolonged disease-free survival compared with placebo (median DFS: 22.4 months vs 11.0 months; HR=0.69, p\<0.001).

The current research focus has expanded to the field of neoadjuvant chemoimmunotherapy, but the adjuvant treatment strategy after such therapy remains a blank slate. Given that esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in our country, it is of great clinical significance to explore adjuvant treatment strategies after neoadjuvant chemoimmunotherapy combined with radical resection.

Based on the above background, we have designed a randomized controlled trial (RCT) to evaluate the efficacy of adjuvant immunotherapy versus observation alone in patients with ESCC after neoadjuvant chemoimmunotherapy, with the hope of providing evidence-based medical evidence for this population.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)

Keywords

  • esophageal squamous cell carcinoma
  • neoadjuvant chemoimmunotherapy
  • Adjuvant immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years.
  • confirmed esophageal squamous cell carcinoma.
  • Preoperative staging of cT1b-cT2N+M0 or cT3-cT4a, any N, M0 (UICC/AJCC TNM staging, 8th edition, 2017), and treated with therapy using an immunotherapy combined with a taxane and platinum regimen, followed by radical surgical resection.
  • R0 resection.
  • Postoperative pathological staging of ≥ypT1 and/or ≥ypN1.
  • (ECOG) performance status (PS) ≤1.
  • Physical examination and imaging studies completed within 4 weeks prior to randomization confirming disease-free status, with imaging studies including CT scans of the chest and abdomen.
  • Normal function of major organs.
  • Women of and men with partners of childbearing potential must agree to use effective during the treatment period and for 6 months before and after the treatment period.
  • Willingness of the subject to participate in the study and provision of .
  • Good compliance of the subject, with the ability to follow up on efficacy and adverse events/reactions as required by the study plan.

Exclusion criteria

Exclusion Criteria:

  • Presence of blood-borne infectious disease (HIV).
  • Presence of psychiatric disorders.
  • History of any other within the past 5 years (except for completely cured cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin).
  • Treatment in the ICU due to severe complications after radical surgery for esophageal cancer.
  • Severe anastomotic stricture after surgery, requiring dilation treatment.
  • Known severe allergy to any component of the study drug.
  • Presence of other diseases, or long-term systemic use of or ; the use of inhaled or topical corticosteroids or equivalent doses of adrenal corticosteroid replacement therapy is permitted.
  • Active (HBV-DNA ≥ 2000 IU/mL or 10⁴ copies/mL), (positive hepatitis C antibody, and HCV-RNA above the lower limit of detection of the assay). Patients with a hepatitis B copy number ≤ 10³ copies/mL after anti-hepatitis B or C treatment may be considered for enrollment at the discretion of the principal investigator.
  • Presence of any unstable systemic disease (including active uncontrolled peptic ulcer, active infection, grade 4 hypertension, unstable angina, congestive heart failure, unstable cerebrovascular disease, thromboembolic disease, hepatic, renal, metabolic diseases, or unhealed fractures, wounds as judged by the surgeon).
  • Patients who are difficult to communicate with or follow up with over the long term.
  • Women who are breastfeeding.
  • Currently participating or planning to participate in other clinical trials.
  • Other situations deemed unsuitable by the physician.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Adjuvant Immunotherapy Group

    For patients with non-pCR esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy, adjuvant immunotherapy with immune checkpoint inhibitors (the same ICIs used before surgery) is administered postoperatively, once every three weeks, for a total of 15 treatments.

    Drug: Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)

  • Active comparator
    Observation Group

    For patients with non-pCR esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy, postoperative observation is conducted without the use of any anti-tumor treatment.

    Other: Observation

Interventions

  • DrugImmune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)

    Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The immune checkpoint inhibitors used for adjuvant therapy after surgery were consistent with those used during the neoadjuvant treatment before surgery, including pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab.

  • OtherObservation

    Postoperative observation is conducted without the use of any anti-tumor treatment.

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS)

    In this study, disease-free survival (DFS) refers to the time from the start of surgery to the first occurrence of disease recurrence or metastasis. If a patient does not experience disease recurrence or metastasis during the follow-up period, their DFS is typically recorded as the time from the start of treatment to the end of follow-up.

    Time frame: From the time of patient enrollment, up to a maximum of 2 years.

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) refers to the time from the start of enrollment to the time of death from any cause. If a patient is still alive at the end of the study, their OS is recorded as the time from the start of the study to the end of the study.

    Time frame: From the time of patient enrollment, up to a maximum of 5 years.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

Of 37 interventional studies with no phase under Esophageal Squamous Cell Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 16, 2025
StartEst.
Jul 20, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07067450
Lead sponsor
Sichuan University
Responsible party
Zhen-Yu Ding (Clinical Professor, Sichuan University) — Principal investigator
First posted
Jul 16, 2025
Start date
Jul 20, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 16, 2025

Study contacts

Qing Li, PhD
Contact
liqing@scu.edu.cn
+8618702848178

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immune checkpoint inhibitors · Pembrolizumab

Start the discussion